Heme oxygenase-1 (HO-1) catalyzes heme degradation, which gives rise to the formation of carbon monoxide (CO), biliverdin, and iron. The upregulation of HO-1 under pathological conditions associated with cellular stress represents an important cytoprotective defense mechanism by virtue of the anti-oxidant properties of the bilirubin and the anti-inflammatory effect of the CO produced. The same mechanism is hijacked by premalignant and cancerous cells. In recent years, however, there has been accumulating evidence supporting that the upregulation of HO-1 promotes cancer progression, independently of its catalytic activity. Such non-canonical functions of HO-1 are associated with its interaction with other proteins, particularly transcription factors. HO-1 also undergoes post-translational modifications that influence its stability, functional activity, cellular translocation, etc. HO-1 is normally present in the endoplasmic reticulum, but distinct subcellular localizations, especially in the nucleus, are observed in multiple cancers. The nuclear HO-1 modulates the activation of various transcription factors, which does not appear to be mediated by carbon monoxide and iron. This commentary summarizes the non-canonical functions of HO-1 in the context of cancer growth and progression and underlying regulatory mechanisms.

**Key Words** Heme oxygenase-1, Cancer, Protein-protein interaction, Post-translational modification

**INTRODUCTION**

Heme oxygenase-1 (HO-1) was first characterized in 1968 as a heme degradative enzyme by Tenhunen and colleagues [1]. Later on, many studies investigated the inducers of HO-1 such as heme, heavy metals, hydrogen peroxide, UV, hyperthermia, hyperoxia, sulfhydryl reagents, inflammatory cytokines, modified lipids, and growth factors [2-4]. The heme degradation catalyzed by HO-1 gives rise to release of carbon monoxide, biliverdin, and iron. Carbon monoxide and iron have anti-oxidant [5], anti-apoptotic [6], and anti-inflammatory activity [7].

Human HO-1 comprises 288 amino acids of which 22 hydrophobic residues are present in the C-terminus [8]. The structure of HO-1 with its bound substrate, heme, has been refined in a crystal form; the heme-binding pocket is formed by two helices termed as proximal and distal helices [9]. In general, HO-1 is anchored to smooth endoplasmic reticulum through a C-terminal transmembrane domain, while the rest of the molecule is cytoplasmic. Endoplasmic reticulum anchored HO-1 faces the cytosol [10,11]. Alternatively, induction by heme and hypoxia promotes HO-1 translocation to plasma membrane [12,13], nucleus [14], and mitochondria [15]. The resistance to oxidative stress often observed in cancer cells is, in part, attributable to the upregulation of HO-1. The HO-1 overexpression correlates with poor prognosis in several malignancies. These include breast cancer [16], renal cancer [17], hepatocellular carcinoma [18], melanoma [19], and pancreatic cancer [20]. The upregulation of HO-1 is associated with cancer cell growth, resistance to anticancer therapy invasiveness, metastasis, angiogenesis, and metabolic reprogramming (Fig. 1).

Besides its canonical role in heme degradation as part of cellular cytoprotection, HO-1 directly regulates the signaling
molecules and events [21-23]. The overexpression of HO-1 in melanoma activates the B-Raf-extracellular signal-regulated kinases (ERK) pathway, thereby stimulating the proliferative signals [24]. HO-1 induces autophagy via the PI3K/AKT signaling pathway, which contributes to pharmorubicin resistance in breast cancer cells [25]. HO-1 promotes the survival signals in renal cancer cells by modulating apoptosis and autophagy regulating molecules [26]. Further, HO-1 induces the epithelial-mesenchymal transition by upregulating expression of metastatic marker genes, snail and twist in prostate cancer [27]. This mini-review highlights the non-canonical functions of HO-1 in the context of regulating redox balance and promoting cancer progression through a canonical mechanism is also involved to some extent.

**CANONICAL MECHANISM**

**Carbon monoxide**

As one of the by-products of HO-1, carbon monoxide can mediate various canonical signaling events involved in promoting tumorigenesis and contribute to poor prognosis in various cancers [28]. Carbon monoxide is a diffusible gas that regulates the synthesis of angiogenic mediators such as VEGF, interleukin 8 (IL-8), and stromal cell-derived factor 1, as shown in Figure 2 [29]. Carbon monoxide also functions as a second messenger that activates soluble guanylyl cyclase followed by cyclic-GMP production, enhancing cellular proliferation [28]. It also modulates the soluble p38 mitogen-activated protein kinase (MAPKs), ERK, and c-Jun N-terminal kinase signaling pathways in cancer cells [28].

**Iron**

Iron is the only metallic by-product of heme degradation catalyzed by HO-1. Iron is essential for various biological process-
es such as oxygen transport, oxidative phosphorylation, DNA biosynthesis, and xenobiotic metabolism [30]. Iron undergoes transition between ferric (Fe$^{3+}$) and ferrous (Fe$^{2+}$) ion via oxidation-reduction reactions [30]. The ferrous iron is stored in ferritin, and the ferritin-bound iron is degraded by autophagy. The iron released during autophagy-mediated ferritin degradation induces ferroptosis [31].

Iron recycling and homeostasis are among the physiological functions of HO-1, but iron overproduction also plays a role in pathological conditions. Intracellular iron levels are maintained by ferroportin and transferrin receptor [32]. "Excusive HO-1 expression decreases ferroportin 1 expression, or increased transferrin receptor expression enhances the labile iron pool, resulting in ferroptosis induction [32]. In the cytosol, iron accumulates in the form of ferric iron as a consequence of heme degradation by HO-1. The ferrous iron reduces hydrogen peroxide to form hydroxyl radical (HO) via the Fenton reaction [33]. The increase in hydroxyl radical formation can cause genomic instability, oxidative DNA damage, and destruction of other biomolecules. The induction of ferroptosis, mitophagy, and ferritinophagy is attributable to overloaded iron [Fig. 2] [34]. Ferroptosis is a regulated cell death primarily caused by iron-mediated oxidative damage to the cell membrane [34]. Hemin and carbon monoxide releasing molecule (CORM), but not biliverdin or bilirubin, accelerate ferroptosis induced by Erastin [35]. Additionally, hemin and CORM induce HO-1 expression and increase membranous lipid peroxidation in the presence of Erastin. Thus, HO-1 is required for iron-dependent lipid peroxidation associated with ferroptosis [35]. The excessive iron accumulated in mitochondria contributed to the proliferation, migration and invasion of osteosarcoma, as well as stimulation of the Warburg effect [36].

NON-CANONICAL MECHANISM

An emerging hypothesis suggests that the biological and cellular functions of HO-1 may in part relate to specific subcellular compartmentalization, and/or may transcend the catalytic breakdown of heme, with certain effector functions that are independent of its enzymatic reaction products [37].

Protein-protein interactions

The HO-1 protein was first crystallized in 1990 [9]. It contains a heme-binding pocket at distal and proximal helices, and C-terminus contains a hydrophobic tail that is essential for membrane binding [38]. It also contains hydrophilic polar residues that regulate oncogenic signaling pathways. The protein-protein interactions were evaluated in clusters by mass spectroscopy and bioinformatics tools.

The protein-protein interactions dictate stability [39], oligomerization [40], and subcellular localization [41] of HO-1 as well as its functions. It is generally accepted that heat shock proteins, functioning as chaperones for tumor antigens, elicit tumor-specific adaptive immune responses [42]. CD91 is a receptor for some heat shock proteins, including HSP70 and GP96 [43]. Based on the HO-1 amino acid sequence homology with Hsp70, CD91 was suggested as a putative binding partner of HO-1 [44]. The HO-1 sequence homology was analyzed using Patch Dock molecular docking algorithm and Fire Dock analysis against CD91 [23]. There are polar residues found in HO-1 including Glu63, Tyr78, Glu81, Glu82, His84, Lys86, Glu90, Gin91, and Gin102 [23]. The polar residues found in CD91 are Arg571, Thr576, Thr536, Arg553, Trp556, and Ser565 [23]. Hydrogen bond interactions are observed between Glu90 (HO-1) and Gly571 (CD91), between Glu63 (HO-1) and Thr576 (CD91), and between Gin102 (HO-1) and Thr536 (CD91). Furthermore, hydrophobic-hydrophobic interactions are observed between Tyr55, Val59 (HO-1) and Val535 (CD91) [23]. Salt bridges are found between Lys177 (HO-1) and Glu332 (CD91) [23].

Self-assembly to form dimers and higher oligomers is a common phenomenon in many membrane proteins, such as receptors, enzymes, neurotransmitter transporters, and ion channels, in which oligomerization is crucial for their proper cellular localization and function [40]. The stabilization of HO-1 through oligomerization in the endoplasmic reticulum was investigated [40]. HO-1 forms dimers/oligomers in the endoplasmic reticulum, which was not observed with a truncated HO-1 lacking the C-terminal transmembrane sequence (amino acids 266-285) [40]. As Trp 270 within the transmembrane sequence is conserved in vertebrate HO-1, it may contribute to a strong thermodynamic force in the interface and plays a prime role in the oligomeric state of HO-1. By utilizing a molecular modeling, Trp 270 was predicted as a potential interfacial residue of transmembrane α-helices essential for protein-protein interactions. The W270N mutation significantly reduced microsomal HO-1 catalytic activity [40]. The decreased Fluorescence Resonance Energy Transfer (FRET) assay efficiency indicates that the W270N mutation appears to disrupt the oligomeric state. These findings indicate that oligomerization is critical for the HO-1 stability and function.

Cleavage of C-terminal transmembrane segment facilitates the nuclear translocation of HO-1 and cancer progression. In HeLa and H1299 cells, overexpression of a truncated HO-1 lacking the transmembrane sequence promoted proliferation, migration, and invasion of these cancer cells [45]. Inhibiting nuclear localization of truncated HO-1 abolished its tumorigenic effect [46]. In alveolar macrophages, the endoplasmic resident HO-1 translocates to the plasma membrane and binds to the caveolin scaffolding domain of caveolin [47].

The association of HO-1 with STAT3 in prostate cancer hampers the nuclear localization of STAT3. Thus, HO-1 interaction inhibits the androgen receptor/STAT3 signaling pathway [48]. 14-3-3 family proteins interact with HO-1, thereby enhancing its stability and activating the STAT3 signaling pathway in hepatocellular carcinoma [39]. The cholesterol-induced hypoxia triggers the association of HO-1 with emopamil-binding protein and activates the AKT signaling pathway.
The LNCaP prostate cancer cells express the truncated 28-kDa HO-1 that is predominantly localized in the nucleus as a complex with nuclear factor-erythroid factor 2-related factor 2 (Nrf2) [50]. Notably, nuclear HO-1 rescued Nrf2 from glycosynthesis kinase 3 beta (GSK3β)-mediated degradation. Further, cells enriched with nuclear HO-1 exhibited a significant increase in transcription of Nrf2 target genes, such as NAD(P)H:quinone oxidoreductase and glucose 6-phosphate dehydrogenase [50]. Thus, the preferential activation of cytoprotective mechanisms through stabilization of Nrf2 by nuclear HO-1 confers long-term tolerance to oxidative injury and cell survival of cancer as well as cells. HO-1 interacts with glucocorticoid receptors, which is responsible for the poor prognosis of prostate cancer [51]. The acetylation of nuclear HO-1 by p300/CREB-binding protein (CBP) histone acetyltransferase facilitates its interaction with Jun D, leading to transcriptional activation of AP-1 [45]. The resulting acetylated HO-1 enhanced growth, migration, and invasiveness of HeLa and H1299 cells, and xenograft tumor growth and metastasis [45].

Post-translational modification

The post-translational modifications represent the key covalent conjugation of proteins. Phosphorylation, acetylation, and ubiquitination are the major post-translational modifications. The principal post-translational modifications of HO-1 and their functional significance are summarized below.

1) Phosphorylation

Phosphorylation is one of the most important post-translational modifications observed in diverse pathophysiologic conditions. It regulates cancer signaling pathways by modulating the activity or stability of target proteins, their interaction with other proteins, subcellular localization, etc. [52]. Based on screening the proteomic data by mass spectrometry, the serine 229 residue of HO-1 was found to be a putative site phosphorylated by TANK binding kinase-1 [53]. Salinas et al. [54] found Ser 188 as the potential site for phosphorylation of HO-1 by AKT/PKB. The phosphorylation sites of HO-1 were predicted by utilizing by in silico bioinformatic tools and public databases such as the human protein database (https://www.hprd.org/). There are about five sites of serine/threonine-phosphorylation (Table 1). HO-1 is likely to be phosphorylated by diverse kinases including AKT, Src kinase, GSK3β, casein kinase 1, ERK, and other MAPKs.

2) Acetylation

Acetylation is another important post-translational modification that regulates the various cellular processes. It influences the protein dynamics such as protein folding, stability, and localization [55]. The HO-1 acetylated by p300/CBP interacts with Jun D at Lys 243 and induces AP-1 transcriptional activity [45]. To explore global acetylation of HO-1, we utilized an algorithm Group-based Prediction System (GPS). We evaluated the potent internal acetylation, using a computational approach called GPS-based prediction of acetylation on internal lysines (PAIL). It evaluates the possible histone acetyltransferases through a BLOSUM 64, amino acid substitution matrix. The algorithm compares the query sequence to an experimental acetylation of a known peptide [56]. As a result, we estimate that among the possible acetylated sites, Lys 143 and Lys 149 are more potential acetylation sites of HO-1 (Table 2). The residues were measured based on a high score with a specific threshold (http://pail.biocuckoo.org/online.php).

Table 1. The prediction of consensus phosphorylation of HO-1 using experimentally curated functional WW domains in phosphorylation site data base

| Position in query protein | Sequence in query protein | Corresponding motif described in the literature | Features of motif described in the literature |
|--------------------------|---------------------------|----------------------------------------------|---------------------------------------------|
| 71-72                    | SP                        | [pS/pT]P                                   | WW domain binding motif                      |
| 229-230                  | SP                        | [pS/pT]P                                   | WW domain binding motif                      |
| 108-109                  | TP                        | [pS/pT]P                                   | WW domain binding motif                      |
| 192-193                  | TP                        | [pS/pT]P                                   | WW domain binding motif                      |
| 252-253                  | TP                        | [pS/pT]P                                   | WW domain binding motif                      |

HO-1, heme oxygenase-1; S, serine; T, threonine; P, proline; WW, proline rich short sequence.

Table 2. The prediction of acetylated sites by GPS-PAIL database

| Peptide | Position | Score | Threshold |
|---------|----------|-------|-----------|
| DLSEALKEATKEV | 18 | 0.76 | 0.2 |
| ALKEATKVKHTQA | 22 | 1.11 | 0.2 |
| VTRDGFKLVMASL | 48 | 1.14 | 0.2 |
| PEELHRKAALEGD | 86 | 0.63 | 0.2 |
| AMQRYVKRLHEVG | 116 | 1.67 | 0.2 |
| SGGQVLKIAKQA | 148 | 1.38 | 0.2 |
| GGQVLKKIAKQAL | 149 | 2.14 | 0.2 |
| LKKAIAQKALDLPS | 153 | 2.27 | 0.2 |
| ASATKDFQLTRSR | 177 | 1.46 | 0.2 |
| RVIEEAKTLFDNL | 204 | 0.81 | 0.2 |
| RQRASNVQDSAP | 243 | 0.59 | 0.2 |
| VETPRGKPPNLTR | 256 | 0.93 | 0.2 |

GPS, Group-based Prediction System; PAIL, prediction of acetylation on internal lysines. K refers the site for N’-lysine acetylation. Higher score indicates the higher probability of acetylation.
3) Ubiquitination

Ubiquitination is a universal post-translational modification, mediated through ubiquitin conjugation at a specific lysine residue of the target protein destined to be degraded by 28S proteasomes. It regulates cellular processes such as DNA repair, inflammation, and endocytosis [57]. Ubiquitination is a critical post-translational modification for destabilizing a protein and regulating various cancer signaling pathways. The translocation in renal carcinoma, chromosome 8 (TRC8), an E3 ubiquitin ligase, interacts with HO-1 and ubiquitinates it, and the lack of trc8 stabilizes HO-1 and elevates its expression, promoting the tumor progression [58]. We implemented the Bayesian decision theory algorithm [59] to investigate potential ubiquitinated residues of HO-1. As a result, it was predicted that Lys 18, Lys 116, Lys 149, and Lys 153 might be potential sites for ubiquitination of HO-1 (Table 3). This computational prediction is useful to analyze more diligent outcomes (http://bdmpub.biocuckoo.org/prediction.php).

Sub-cellular localization

HO-1 was initially purified as a 32-kDa microsomal protein mainly found in the smooth endoplasmic reticulum. However, HO-1 can also translocate into the plasma membrane, mitochondria, and nucleus under some stress conditions [12,60,61]. Caveolin 1 is a scaffolding protein and the main component of flask-shaped plasma membrane invaginations called caveolae. HO-1 binds to caveolin 1, and thereby induces the polarization of M1 to M2 macrophages and down-regulates IL-6 and other inflammatory cytokines [47]. The mitochondrial translocation of HO-1 induces mitophagy and promotes ferroptosis in breast cancer cells [32]. A 28-kDa HO-1 protein with truncation of the C-terminal amino acids lacking the membrane-bound domain was found in the nucleus [41,46].

| Peptide      | Position | Score | Threshold |
|--------------|----------|-------|-----------|
| QDLSKELKATKEVH | 18       | 2.14  | 0.3       |
| EALKETKEVHTQAE | 22       | 1.65  | 0.3       |
| QVTRDGFKLVMASLY | 48       | 1.26  | 0.3       |
| FPEELHRKAALQDLD | 86       | 0.92  | 0.3       |
| PMQKRLHELVRK | 116      | 2.27  | 0.3       |
| LGQKQLKIQAKA | 148      | 1.34  | 0.3       |
| SGQQLKIQAKALD | 149     | 2.40  | 0.3       |
| VKKIAQKALGPLSS | 153    | 2.69  | 0.3       |
| PNIASTKKFQLYRS | 177     | 0.46  | 0.3       |
| QFQIEEAKTAFLNNI | 204    | 0.49  | 0.3       |
| LQRASNVQDAP | 243      | 0.47  | 0.3       |
| PVTPRGKPPLTR | 256      | 0.78  | 0.3       |

Table 3. The prediction of ubiquitinated sites in HO-1 by BDT algorithm

HO-1, heme oxygenase-1; BDT, Bayesian decision theory; K, Lysine residues potentially ubiquitinated. Higher score indicates the higher probability of ubiquitination.

1) Mitochondrial HO-1

Mitochondria is one of the key generators of reactive oxygen species. HO-1 translocates to the mitochondria in a truncated form. The mitochondrial HO-1 accumulates in the presence of cellular stress such as smoking, oxidative stress, and hypoxia [15,60,62]. Mitochondrial HO-1 induces mitophagy and ferroptosis in breast cancer cells treated with BAY117085, an NF-κB inhibitor [32]. Mitochondrial HO-1 accumulation alters mitochondrial protein profiles, regulates redox potential, and promotes tumorigenesis [15].

2) Nuclear HO-1

HO-1 is prone to undergo intramembrane proteolysis which facilitates its migration from the endoplasmic reticulum to the nucleus to promote cancer growth and invasiveness regardless of its enzymatic activity [49]. The transmembrane sequence region of HO-1 is located at the carboxyl end, and HO-1 is subjected to proteolytic cleavage to produce a truncated form that consists of 237 amino acids and 28 kDa fragments [41]. Although bioinformatic analysis predicted a monopartite nuclear localization sequence at position 111 and a bipartite nuclear localization sequence at position 196 for HO-1, it is unknown whether an importin-related mechanism mediates nuclear HO-1 import [23]. On the other hand, a lysine-rich region is highly homologous to a nuclear export motif on the HO-1 protein, and its function establishes through interaction with chromosomal maintenance region protein 1 [41].

While devoid of heme-degrading activity, nuclear HO-1 has been considered as a regulator of nuclear transcription factors [37]. For instance, the HO-1 protein in the nucleus inhibits DNA binding activity of NF-κB while activating core-binding protein (CBF), Brain-specific homeobox/POU domain protein 3, and AP-2 transcription factors [41]. Interestingly, depending on the type of stimulus, truncated HO-1 can either protect or kill cells. For example, both full-length HO-1 and truncated HO-1 expression protect cells from death when exposed to oxidative conditions [41].

Sacca et al. [61] reported that nuclear HO-1 might be involved in the development of prostate cancer. The truncated HO-1 promotes autophagy, thereby inducing chemoresistance in Her2 targeted therapy [63]. The truncated HO-1 acetylated by p300/CPB in nucleus interacts with JunD and stimulates AP-1 transcriptional activity in H1299 and HeLa cells, promoting their growth and migration [45]. The expression and subcellular localization of HO-1 increased with tumor progression in a mouse model of squamous cell carcinoma and head and neck squamous cell carcinoma [64]. Taken together, these findings suggest that aberrant HO-1 overexpression in head and neck squamous cell carcinoma and its nuclear localization is associated with malignant progression. Birrane et al. [65] have reported that cigarette smoke-induced nuclear translocation of HO-1 promotes the secretion of VEGF in prostate cancer cells.
The DNA G4 quadruplexes (G4) structures comprise the members of helicase superfamilies such as SF1, Pif1, or SF2, RecQ, Fanconi anemia group J protein, Bloom syndrome protein, and Werner syndrome protein [66]. The G4 structures are key regulators of oncogenes and cancer driving genes such as c-MYC, K-RAS, PDGF-A, and VEGF-A [67]. The nuclear HO-1 interacts with G4 structures, and thereby promotes genome instability and DNA damage responses [68]. The proximal ligation assay data verifies the interaction between HO-1 and quadruplex DNA [68].

Clinical significance of HO-1
Nuclear HO-1 has been shown to be expressed aberrantly in many cancers. HO-1 is localized in the nuclear compartment of metastatic prostate cancer but not in benign prostatic hypertrophy [61]. Similarly, HO-1 immunoreactive protein is detected in the nucleus of malignant head and neck cancer; nuclear localization of HO-1 is associated with tumor progression of head and neck squamous cell carcinomas [64].

HO-1 bound to an Nrf2 immunoreactive fragment and altered cellular metabolism by preferentially inducing specific Nrf2 downstream genes such as glucose-6-phosphate dehydrogenase. The LNCaP prostate cancer cells are constitutively enriched with the 28-kDa truncated form of HO-1 that resides in the nucleus as a complex with Nrf2 [50]. Nuclear HO-1 stabilizes Nrf2 by protecting it from GSK3β-mediated degradation. As a result, it is associated with an increase in resistance to glucose deprivation, implying a preference for the hexose monophosphate shunt pathway [50]. The nuclear retention and activation of Nrf2 induce transcriptional regulation of antioxidant enzymes and may enable a feed forward adaptive reprogramming for recovery and a survival advantage of cancer cells under oxidative stress [50].

Though HO-1 overexpression plays a role in tumor progression, it also has an opposite function in some cancer cells. STAT3 mediates the activation of the androgen receptor which is a key step in the development of prostate cancer. Elguero et al. [48] demonstrated that the HO-1 protein could interact with STAT3 and enhance the cytoplasmic retention of this transcription factor, leading to repression of its transcriptional activity in prostate cancer cells. Given that STAT3 regulates cell proliferation, migration, and invasion via androgen receptor signaling involved in inflammation and angiogenesis, blockage of STAT3-androgen receptor axis by HO-1 through direct interaction with STAT3 represents a novel function for HO-1 in prostate cancer, beyond its conventional role in heme degradation [48].

Another mechanism by which HO-1 modulates tumor growth and progression may involve suppression of NF-κB activation and subsequent transcription of angiogenic as well as inflammatory genes, particularly those encoding VEGF, HIF-1α, and α5β1 integrin [69]. These findings propose HO-1 as a novel modulator of the angiogenic switch in prostate cancer [69]. So clinical application of HO-1 inhibitors or inducers/activators is controversial due to its dual functions in proliferation and progression of cancer cells.

CONCLUSION AND FUTURE PERSPECTIVES
Carbon monoxide and iron accumulated during HO-1-mediated heme degradation play a pivotal role in signal transduction in various malignancies. The upregulation of carbon monoxide production promotes angiogenesis in several cancers. The iron mediates mitophagy, ferroptosis, and ferritinophagy, that modulate cancer development and progression.

The non-canonical mechanisms underlying oncogen-
ic functions of HO-1 include protein-protein interactions, post-translational modifications, and sub-cellular localization (Fig. 3). HO-1 binds to other proteins and activates signaling pathways involved in growth, survival, migration, invasion, and metastasis of cancer cells. The post-translational modification of HO-1, such as acetylation, ubiquitination, and phosphorylation, modulates the stability function, and sub-cellular localization of this enzyme. The translocation of HO-1 into the nucleus modulates activity of transcription factors and their regulators involved in tumorigenesis.

We investigated potential residues for principal post-translational modifications of HO-1 by using in silico techniques. The proteomics analysis can also facilitate prediction of putative sites for post-translational modification in HO-1. The non-canonical mechanisms of HO-1 merit further investigations as a novel therapeutic target.

**FUNDING**

This research was supported by a Basic Science Research Program (2021R1I1A1A01046540) and the BK21 FOUR Program (5120200513755) from the National Research Foundation (NRF), Ministry of Science and ICT, Republic of Korea.

**CONFLICTS OF INTEREST**

No potential conflicts of interest were disclosed.

**ORCID**

Achanta Sri Venakata Jagadeesh, https://orcid.org/0000-0002-6073-7202

Xizhu Fang, https://orcid.org/0000-0001-6926-6614

Seong Hoon Kim, https://orcid.org/0000-0002-6573-9071

Yanmee N. Guillen-Quispe, https://orcid.org/0000-0003-2157-4727

Jie Zheng, https://orcid.org/0000-0002-6446-2250

Young-Joon Surh, https://orcid.org/0000-0001-8310-1795

Su-Jung Kim, https://orcid.org/0000-0002-3636-0644

**REFERENCES**

1. Tenhunen R, Marver HS, Schmid R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci USA 1968;61:748-55.

2. Keyse SM, Tyrrell RM. Heme oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite. Proc Natl Acad Sci USA 1989;86:99-103.

3. Alam J, Shibahara S, Smith A. Transcriptional activation of the heme oxygenase gene by heme and cadmium in mouse hepatoma cells. J Biol Chem 1989;264:6371-5.

4. Foresti R, Clark JE, Green CJ, Motterlini R. Thiol compounds interact with nitric oxide in regulating heme oxygenase-1 induction in endothelial cells. Involvement of superoxide and peroxynitrite anions. J Biol Chem 1997;272:18411-7.

5. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science 1987;235:1043-6.

6. Al-Owais MM, Scragg JL, Dallas M, Boycott HE, Warburton P, Chakrabarty A, et al. Carbon monoxide mediates the anti-apoptotic effects of heme oxygenase-1 in medulloblastoma DAOY cells via K⁺ channel inhibition. J Biol Chem 2012;287:24754-64.

7. Otterbein LE, Bach FH, Alam J, Soares M, Tao Lu H, Wysk M, et al. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat Med 2000;6:422-8.

8. Kochert BA, Fleischhacker AS, Wales TE, Becker DF, Engen JR, Ragsdale SW. Dynamic and structural differences between heme oxygenase-1 and -2 are due to differences in their C-terminal regions. J Biol Chem 2019;294:8259-72.

9. Schuller DJ, Wilks A, Ortiz de Montellano PR, Poulos TL. Crystal structure of human heme oxygenase-1. Nat Struct Biol 1999;6:860-7.

10. Gottlieb Y, Truman M, Cohen LA, Leichtmann-Bardoogo Y, Meyron-Holtz EG. Endoplasmic reticulum anchored heme oxygenase-1 faces the cytosol. Haematologica 2012;97:1489-93.

11. Yoshida T, Sato M. Posttranslational and direct integration of heme oxygenase into microsomes. Biochem Biophys Res Commun 1989;163:1086-92.

12. Kim HP, Wang X, Galbiati F, Ryter SW, Choi AM. Caveolae compartmentalization of heme oxygenase-1 in endothelial cells. FASEB J 2004;18:1090-9.

13. Dunn LL, Midwinter RG, Ni J, Hamid HA, Parish CR, Stocker R. New insights into intracellular locations and functions of heme oxygenase-1. Antioxid Redox Signal 2014;20:1723-42.

14. Mascaró M, Alonso EN, Alonso EG, Lacunza E, Curino AC, Facchinetti MM. Nuclear localization of heme oxygenase-1 in pathophysiological conditions: does it explain the dual role in cancer? Antioxidants (Basel) 2021;10:87.

15. Converso DP, Taillé C, Carreras MC, Jaitovich A, Poderoso JJ, Boczkowski J. HO-1 is located in liver mitochondria and modulates mitochondrial heme content and metabolism. FASEB J 2006;20:1236-8. Erratum in: FASEB J 2006;20:1573.

16. Deng R, Wang SM, Yin T, Ye TH, Shen GB, Li L, et al. Inhibition of tumor growth and alteration of associated macrophage cell type by an HO-1 inhibitor in breast carcinoma-bearing mice. Oncol Res 2013;20:473-82.

17. Goodman AI, Choudhury M, da Silva JL, Schwartzman ML, Abraham NG. Overexpression of the heme oxygenase gene in renal cell carcinoma. Proc Soc Exp Biol Med 1997;214:54-61.

18. Zou C, Zou C, Cheng W, Li Q, Han Z, Wang X, et al. Heme oxygenase-1 retards hepatocellular carcinoma progression through the microRNA pathway. Oncol Rep 2016;36:2715-22.

19. Was H, Cichon T, Smolarczyk R, Rudnicka D, Stopa M, Chevalier C, et al. Overexpression of heme oxygenase-1 in
murine melanoma: increased proliferation and viability of tumor cells, decreased survival of mice. Am J Pathol 2006;169:2181-98.
20. Sunamura M, Duda DG, Ghattas MH, Lozonschi L, Motoi F, Yamauchi J, et al. Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer. Angiogenesis 2003;6:15-24.
21. Wu J, Li S, Li C, Cui L, Ma J, Hui Y. The non-canonical effects of heme oxygenase-1, a classical fighter against oxidative stress. Redox Biol 2021;47:102170.
22. Consoli S, Sorrenti V, Grosso S, Vanella L. Heme oxygenase-1 signaling and redox homeostasis in physiopathological conditions. Biomolecules 2021;11:589.
23. Vanella L, Barbagallo I, Tibullo D, Forte S, Zappalà A, Li Volti G. The non-canonical functions of the heme oxygenases Oncotarget 2016;7:69075-86.
24. Liu L, Wu Y, Bian C, Nisar MF, Wang M, Hu X, et al. Heme oxygenase 1 facilitates cell proliferation via the B-Raf-ERK signaling pathway in melanoma. Cell Comm Unit 2019;17:3.
25. Pei L, Kong Y, Shao C, Yue X, Wang Z, Zhang N. Heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to phormorubicin by promoting autophagy via PI3K/Akt pathway. J Cell Mol Med 2018;22:5311-21.
26. Banerjee P, Basu A, Wegiel B, Otterbein LE, Mizumura K, Gasser M, et al. Heme oxygenase-1 promotes survival of renal cancer cells through modulation of apoptosis- and autophagy-regulating molecules. J Biol Chem 2012;287:32113-23.
27. Nemeth Z, Li M, Csizmadia E, Döme B, Johansson M, Persson J, et al. Heme oxygenase-1 in macrophages controls prostate cancer progression. Oncotarget 2015;6:33675-88.
28. Chiang SK, Chen SE, Chang LC. A dual role of heme oxygenase-1 in cancer cells. Int J Mol Sci 2018;20:39.
29. Dulaš J, Désanne J, Jożkowicz A, Agarwal A. Heme oxygenase-1 and carbon monoxide in vascular pathobiology: focus on angiogenesis. Circulation 2008;117:231-41.
30. MacKenzie EL, Iwasaki K, Tsuji Y. Intracellular iron transport and storage: from molecular mechanisms to health implications. Antioxid Redox Signal 2008;10:997-1030.
31. Zhang Y, Mikhail M, Xu D, Li Y, Soe-Lin S, Ning B, et al. Lysosomal proteolysis is the primary degradation pathway for cytosolic ferritin and cytosolic ferritin degradation is necessary for iron exit. Antioxid Redox Signal 2010;13:3311-23.
32. Chang LC, Chiang SK, Chen SE, Yu YL, Chou RH, Chang WC. Heme oxygenase-1 mediates BAY 11-7085 induced ferroptosis. Cancer Lett 2018;416:124-37.
33. Papanikolaou G, Pantopoulos K. Iron metabolism and toxicity. Toxicol Appl Pharmacol 2005;202:199-211.
34. Tang D, Chen X, Kang R, Kroemer G. Ferroptosis: molecular mechanisms and health implications. Cell Res 2021;31:107-25.
35. Kwon MY, Park E, Lee SJ, Chung SW. Heme oxygenase-1 accelerates erastin-induced ferroptotic cell death. Oncotarget 2015;6:24393-403.
36. Ni S, Kuang Y, Yuan Y, Yu B. Mitochondrion-mediated iron accumulation promotes carcinogenesis and Warburg effect through reactive oxygen species in osteosarcoma. Cancer Cell Int 2020;20:399.
37. Ryter SW. Heme oxygenase-1, a cardinal modulator of regulated cell death and inflammation. Cells 2021;10:515.
38. Rahman MN, Vukomanovic D, Vlahakis JZ, Szarek WA, Nakatsu K, Jia Z. Structural insights into human heme oxygenase-1 inhibition by potent and selective azole-based compounds. J R Soc Interface 2013;10:20120697.
39. Song J, Zhang X, Liao Z, Liang H, Chu L, Dong W, et al. 14-3-3ζ inhibits heme oxygenase-1 (HO-1) degradation and promotes hepatocellular carcinoma proliferation: involvement of STAT3 signaling. J Exp Clin Cancer Res 2019;38:3.
40. Hwang HW, Lee JR, Chou KY, Suen CS, Hwang MJ, Chen C, et al. Oligomerization is crucial for the stability and function of heme oxygenase-1 in the endoplasmic reticulum. J Biol Chem 2009;284:22672-9.
41. Lin Q, Weis S, Yang G, Weng YH, Helston R, Rish K, et al. Heme oxygenase-1 protein localizes to the nucleus and activates transcription factors important in oxidative stress. J Biol Chem 2007;282:20621-33.
42. Facciponte JG, Wang XY, MacDonald IJ, Park JE, Arnouk D, Grimm MJ, et al. Heat shock proteins HSP70 and GP96: structural insights. Cancer Immunol Immunother 2006;55:339-46.
43. Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001;14:303-13.
44. Li Volti G, Galvano F, Frigiola A, Guccione S, Di Giacomo C, Forte S, et al. Potential immunoregulatory role of heme oxygenase-1 in human milk: a combined biochemical and molecular modeling approach. J Nutr Biochem 2010;21:865-71.
45. Hsu FF, Chiang MT, Li FA, Yeh CT, Lee WH, Chau LY. Acetylation is essential for nuclear heme oxygenase-1-enhanced tumor growth and invasiveness. Oncogene 2017;36:6805-14.
46. Hsu FF, Yeh CT, Sun YJ, Chiang MT, Lan WM, Li FA, et al. Signal peptide peptidase-mediated nuclear localization of heme oxygenase-1 promotes cancer cell proliferation and invasion independent of its enzymatic activity. Oncogene 2015;34:2360-70. Erratum in: Oncogene 2015;34:2410-1.
47. Weng P, Zhang XT, Sheng Q, Tian WF, Chen JL, Yuan JJ, et al. Caveolin-1 scaffolding domain peptides enhance anti-inflammatory effect of heme oxygenase-1 through interrupting its interaction with caveolin-1. Oncotarget 2017;8:40104-14.
48. Elguero B, Guerón G, Giudice J, Toscani MA, De Luca P, Palazar F, et al. Unveiling the association of STAT3 and HO-1 in prostate cancer: role beyond heme degradation. Neoplasia 2012;14:1043-56.
49. Jin X, Xu Z, Cao J, Yan R, Xu R, Ran R, et al. HO-1/EBP interaction alleviates cholesterol-induced hypoxia through the activation of the AKT and Nrfl2/mTOR pathways and inhibition of carbohydrate metabolism in cardiomyocytes. Int J Mol Med 2017;39:1409-20.
50. Biswas C, Shah N, Muthu M, La P, Fernando AP, Sengupta S, et al. Nuclear heme oxygenase-1 (HO-1) modulates subcellular
distribution and activation of Nrf2, impacting metabolic and anti-
oxidant defenses. J Biol Chem 2014;289:26882-94.
51. Leonardi DB, Anselmino N, Brandani JN, Jaworski FM, Páez
AV, Mazaira G, et al. Heme oxygenase 1 impairs glucocorticoid
receptor activity in prostate cancer. Int J Mol Sci 2019;20:1006.
52. Leutert M, Entwisle SW, Villén J. Decoding post-translational
modification crosstalk with proteomics. Mol Cell Proteomics
2021;20:100129.
53. Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR,
Wang P, et al. Proteogenomics connects somatic mutations to
signalling in breast cancer. Nature 2016;534:55-62.
54. Salinas M, Wang J, Rosa de Sagarras M, Martín D, Rojo AI,
Martín-Perez J, et al. Protein kinase Akt/PKB phosphorylates
heme oxygenase-1 in vitro and in vivo. FEBS Lett 2004;578:90-
4.
55. Christensen DG, Xie X, Basisty N, Byrnes J, McSweeney S,
Schilling B, et al. Post-translational protein acetylation: an elegant
mechanism for bacteria to dynamically regulate metabolic
functions. Front Microbiol 2019;10:1604.
56. Deng W, Wang C, Zhang Y, Xu Y, Zhang S, Liu Z, et al. GPS-
PAIL: prediction of lysine acetyltransferase-specific modification
sites from protein sequences. Sci Rep 2016;6:39787.
57. Song L, Luo ZQ. Post-translational regulation of ubiquitin
signaling. J Cell Biol 2019;218:1776-86.
58. Lin PH, Lan WM, Chau LY. TRC8 suppresses tumorigenesis
through targeting heme oxygenase-1 for ubiquitination and
degradation. Oncogene 2013;32:2325-34.
59. Xue Y, Li A, Wang L, Feng H, Yao X. PPSP: prediction of PK-
specific phosphorylation site with Bayesian decision theory. BMC
Bioinformatics 2006;7:163.
60. Bansal S, Biswas G, Avadhani NG. Mitochondria-targeted
heme oxygenase-1 induces oxidative stress and mitochondrial
dysfunction in macrophages, kidney fibroblasts and in chronic
alcohol hepatotoxicity. Redox Biol 2013;2:273-83.
61. Sacca P, Meiss R, Casas G, Mazza O, Calvo JC, Navone N, et
al. Nuclear translocation of haeme oxygenase-1 is associated to
prostate cancer. Br J Cancer 2007;97:1683-9.
62. Slebos DJ, Ryter SW, van der Toorn M, Liu F, Guo F, Baty CJ, et
al. Mitochondrial localization and function of heme oxygenase-1
in cigarette smoke-induced cell death. Am J Respir Cell Mol Biol
2007;36:409-17.
63. Tracey N, Creedon H, Kemp AJ, Culley J, Muir M, Klinowska
T, et al. HO-1 drives autophagy as a mechanim of resistance
against HER2-targeted therapies. Breast Cancer Res Treat
2020;179:543-55.
64. Gandini NA, Fermento ME, Salomón DG, Blasco J, Patel V,
Gutkind JS, et al. Nuclear localization of heme oxygenase-1 is
associated with tumor progression of head and neck squamous
cell carcinomas. Exp Mol Pathol 2012;93:237-45.
65. Birrane G, Li H, Yang S, Tachado SD, Seng S. Cigarette smoke
induces nuclear translocation of heme oxygenase 1 (HO-
1) in prostate cancer cells: nuclear HO-1 promotes vascular
endothelial growth factor secretion. Int J Oncol 2013;42:1919-28.
66. Paeschke K, Bochman ML, Garcia PD, Cejka P, Friedman
KL, Kowalczykowski SC, et al. Pif1 family helicases suppress
genoce instability at G-quadruplex motifs. Nature 2013;497:458-
62.
67. Brooks TA, Kendrick S, Hurley L. Making sense of G-quadruplex
and i-motif functions in oncogene promoters. FEBS J
2010;277:3459-69.
68. Krzeptowski W, Chudy P, Sokolowski G, Żukowska M,
Kusienicka A, Seretny A, et al. Proximity ligation assay
detection of protein-DNA interactions-is there a link between
heme oxygenase-1 and G-quadruplexes? Antioxidants (Basel)
2021;10:94.
69. Ferrando M, Gueron G, Elguero B, Giudice J, Salles A, Leskow
FC, et al. Heme oxygenase 1 (HO-1) challenges the angiogenic
switch in prostate cancer. Angiogenesis 2011;14:467-79.